-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $0.5 Price Target

Benzinga·02/18/2026 12:12:28
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $0.5 price target.